Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

News Release

Wave Life Sciences to Present at the Jefferies 2019 Healthcare Conference

May 22, 2019 at 4:15 PM EDT

CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference in New York on Wednesday, June 5, 2019 at 2:00 p.m. ET.

A live webcast of the presentation will be available on the investor relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. A replay of the presentation will be archived and available at that site for a limited time following the event.

About Wave Life Sciences

Wave Life Sciences (NASDAQ: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media and Patient Contact:
José Juves
617-949-4708
jjuves@wavelifesci.com

WAVE LOGO NEW COLOR SWOOSH.jpg

Source: Wave Life Sciences